Table 1.
The basic characteristics of enrolled patients treated with posaconazole as prophylaxis or therapy medication.
| Prophylaxis N = 456 | Therapy (≥7 days) N = 243 | ||
| Age (year) | Number | 456 | 243 |
| Mean (SD) | 37.4 (16.5) | 37.7 (17.0) | |
| Gender, n (%) | Male | 254 (55.7) | 154 (63.4) |
| Female | 202 (44.3) | 89 (36.6) | |
| Weight (kg) | Mean (SD) | 60.9 (14.1) | 58.9 (12.7) |
| ECOG score, n (%) | 0 | 99 (21.7) | 56 (23.0) |
| 1 | 195 (42.8) | 86 (35.4) | |
| 2 | 103 (22.6) | 54 (22.2) | |
| 3 | 51 (11.2) | 38 (15.6) | |
| 4 | 8 (1.8) | 9 (3.7) | |
| 5 | 0 | 0 | |
| ANC/mm3, n (%) | |||
| ANC ≥1000 | ANC ≥1500 | 184 (40.4) | 149 (61.3) |
| ANC 1000–1500 | 44 (9.6) | ||
| ANC 500–1000 | 47 (10.3) | 30 (12.3) | |
| ANC <500 | ANC 100–500 | 85 (18.6) | 64 (26.3) |
| ANC <100 | 75 (16.4) | ||
| Not measured | 21 (4.6) | 0 | |
| Comorbidities, n (%) | Diabetes | 25 (5.5) | 13 (5.3) |
| Chronic hepatitis | 26 (5.7) | 19 (7.8) | |
| Gastroesophageal disease | 7 (1.5) | 5 (2.1) | |
| Acquired immunodeficiency | 0 | 3 (1.2) | |
| Hereditary immunodeficiency | 2 (0.4) | 0 | |
| Autoimmune disease | 5 (1.1) | 2 (0.8) | |
| Adverse events of posaconazole, n (%) | Diarrhea | 40 (8.8) | 17 (7.0) |
| Vomit | 35 (7.7) | 12 (4.9) | |
| Diagnosis of primary hematologic diseases | |||
| Diagnoses of the full analysis set, n (%) | Hematological malignancies | 416 (91.2) | 219 (90.1) |
| Missing | 0 | 0 | |
| Type of hematological malignancies, n (%) | ALL | 86 (20.7) | 59 (26.9) |
| AML | 228 (54.8) | 102 (46.6) | |
| CLL | 2 (0.5) | 0 | |
| CML | 7 (1.7) | 6 (2.7) | |
| MDS | 20 (4.8) | 17 (7.8) | |
| MM | 15 (3.6) | 11 (5.0) | |
| NHL | 34 (8.2) | 14 (6.4) | |
| Others | 24 (5.8) | 10 (4.6) | |
| Total | 416 (100.0) | 219 (100.0) | |
| Type of transplantation, n (%) | Homogenic | 5 (2.7) | 1 (0.9) |
| Allogeneic | 154 (81.9) | 96 (88.9) | |
| Autologous | 29 (15.4) | 11 (10.2) | |
| Total | 188 (100.0) | 108 (100.0) | |
| Posaconazole used in patients treated with chemotherapy, n (%) | No | 28 (10.4) | 28 (20.7) |
| Yes | 240 (89.6) | 107 (79.3) | |
| Type of chemotherapy, n (%) | Consolidate | 116 (48.3) | 54 (50.5) |
| Induction | 122 (50.8) | 51 (47.7) | |
| Other | 2 (0.8) | 2 (1.9) | |
| Total | 240 (100.0) | 107 (100.0) | |